{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:10Z","timestamp":1781643250395,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Proper Use Promotion Project for Pregnant and Breast-feeding Women funded by the Ministry of Health, Labour and Welfare"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19mk0101086h0003"],"award-info":[{"award-number":["JP19mk0101086h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins are generally recommended to be discontinued once pregnancy is recognized; however, unintentional exposure during early pregnancy may occur in women receiving long-term lipid-lowering therapy, and clinical decision-making often requires careful consideration of potential risks and benefits. We aimed to evaluate the risk of congenital anomalies detected at 1 month and perinatal outcomes among infants born to women exposed to statins during early pregnancy (4\u201313 weeks of gestation) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Japan Drug Information Institute in Pregnancy database (2005\u20132017), we compared pregnant women exposed to statins during early pregnancy (statin-exposed group) and unexposed controls. Neonatal congenital anomalies at 1 month among live births were the primary outcome; secondary outcomes included pregnancy outcomes such as live birth, miscarriage, abortion, and stillbirth. Propensity score matching (1:1) was conducted to estimate the associations between statin exposure and pregnancy outcomes, and inverse probability weighting was performed using stabilized weights as a sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 968 eligible pregnant women, 65 were in the statin-exposed group and 903 in the control group. After propensity score matching, the prevalence of congenital anomalies did not significantly differ between the statin-exposed (1.6%) and control (1.6%) groups, however, estimates were imprecise (odds ratio: 1.00; 95% confidence interval: 0.06\u201315.99). Increased risks of preterm birth (risk ratio: 4.26 [2.02\u20138.99]) and low birth weight (risk ratio: 3.32 [1.73\u20136.36]) were observed in the IPW analysis but not in the primary PSM analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No increase was observed in congenital anomalies detected at 1 month among live births following early statin exposure, although the estimates were imprecise and the study was underpowered for rare outcomes. Higher risks of preterm birth and low birth weight were observed in weighted analyses but not in the primary propensity score\u2013matched analysis. Further research is needed to clarify perinatal risks associated with statin use in pregnancy. These findings may help inform individualized shared decision-making for women who require statin therapy during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-08932-6","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:04:31Z","timestamp":1773493471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pregnancy and neonatal outcomes following statin exposure in early pregnancy: a nationwide consultation-based cohort study in Japan"],"prefix":"10.1186","volume":"26","author":[{"given":"Izumi","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Koinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Murashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"8932_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/pds.4176","volume":"26","author":"A McGrogan","year":"2017","unstructured":"McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26:843\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8932_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2018.07.002","volume":"269","author":"MS Lee","year":"2018","unstructured":"Lee MS, Hekimian A, Doctorian T, Duan L. Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. Int J Cardiol. 2018;269:111\u20133.","journal-title":"Int J Cardiol"},{"key":"8932_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","volume":"32","author":"DF Graham","year":"2021","unstructured":"Graham DF, Raal FJ. Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 2021;32:370\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"8932_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12884-023-05810-3","volume":"23","author":"N Mitsuda","year":"2023","unstructured":"Mitsuda N, Eitoku M, Yamasaki K, J-p NA, Fujieda M, Maeda N, et al. Association between maternal cholesterol level during pregnancy and placental weight and birthweight ratio: data from the Japan Environment and Children\u2019s Study. BMC Pregnancy Childbirth. 2023;23:484.","journal-title":"BMC Pregnancy Childbirth"},{"key":"8932_CR5","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA\/ACC\/AACVPR\/AAPA\/ et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73:e285\u2013350","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"8932_CR6","unstructured":"US Food and Drug Administration. MEVACOR\u00ae (lovastatin) Tablets, for oral use [Prescribing Information]. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019643s088lbl.pdf."},{"key":"8932_CR7","unstructured":"FDA requests removal of strongest warning. against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins; 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy."},{"key":"8932_CR8","unstructured":"JA Society. The 2022 guidelines for the diagnosis and treatment of adult familial hypercholesterolemia (FH); 2022. https:\/\/square.umin.ac.jp\/~jslpc\/pdf\/JAS_FH_GL2022.pdf."},{"key":"8932_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.reprotox.2008.06.009","volume":"26","author":"N Taguchi","year":"2008","unstructured":"Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, et al. Prenatal exposure to HMG-CoA Reductase Inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175\u20137.","journal-title":"Reprod Toxicol"},{"key":"8932_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5551\/jat.RV17033","volume":"26","author":"H Makino","year":"2019","unstructured":"Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, et al. Familial hypercholesterolemia and lipoprotein apheresis. J Atheroscler Thromb. 2019;26:679\u201387.","journal-title":"J Atheroscler Thromb"},{"key":"8932_CR11","doi-asserted-by":"publisher","first-page":"e2141321","DOI":"10.1001\/jamanetworkopen.2021.41321","volume":"4","author":"JC Chang","year":"2021","unstructured":"Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin exposure during pregnancy. JAMA Netw Open. 2021;4:e2141321.","journal-title":"JAMA Netw Open"},{"key":"8932_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cga.12547","volume":"64","author":"N Yakuwa","year":"2024","unstructured":"Yakuwa N, Murashima A, Miyazaki S. Investigation on the accumulation of background and pregnancy outcome information on cases consulted by the Japan Drug Information Institute in Pregnancy. Congenit Anom (Kyoto). 2024;64:6\u201316.","journal-title":"Congenit Anom (Kyoto)"},{"key":"8932_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.35772\/ghm.2020.01120","volume":"3","author":"A Murashima","year":"2021","unstructured":"Murashima A, Yakuwa N, Koinuma S, Uno C, Takai C, Fujioka I, et al. The advances in dealing with the safety of medicated drugs in pregnancy. Glob Health Med. 2021;3:175\u20139.","journal-title":"Glob Health Med"},{"key":"8932_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/cga.12577","volume":"64","author":"M Goto","year":"2024","unstructured":"Goto M, Anzai T, Yamane R, Yakuwa N, Takahashi K, Murashima A. Pregnancy outcomes after first-trimester exposure to fluoroquinolones: findings based on an integrated database from two Japanese institutions. Congenit Anom (Kyoto). 2024;64:199\u2013206.","journal-title":"Congenit Anom (Kyoto)"},{"key":"8932_CR15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1111\/jog.14709","volume":"47","author":"K Hishinuma","year":"2021","unstructured":"Hishinuma K, Yamane R, Yokoo I, Arimoto T, Takahashi K, Goto M, et al. Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study. J Obstet Gynaecol Res. 2021;47:1704\u201310.","journal-title":"J Obstet Gynaecol Res"},{"key":"8932_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cga.12471","volume":"62","author":"S Hatakeyama","year":"2022","unstructured":"Hatakeyama S, Goto M, Yamamoto A, Ogura J, Watanabe N, Tsutsumi S, et al. The safety of pranlukast and montelukast during the first trimester of pregnancy: a prospective, two-centered cohort study in Japan. Congenit Anom (Kyoto). 2022;62:161\u20138.","journal-title":"Congenit Anom (Kyoto)"},{"key":"8932_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/cga.12456","volume":"62","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Yamada T, Goto M, Kawasaki H, Wada T, Ikeda-Sakai Y, et al. Analysis of triptan use during pregnancy in Japan: A case series. Congenit Anom (Kyoto). 2022;62:78\u201381.","journal-title":"Congenit Anom (Kyoto)"},{"key":"8932_CR18","doi-asserted-by":"publisher","first-page":"21m14081","DOI":"10.4088\/JCP.21m14081","volume":"83","author":"N Yakuwa","year":"2022","unstructured":"Yakuwa N, Takahashi K, Anzai T, Ito N, Goto M, Koinuma S, et al. Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. J Clin Psychiatry. 2022;83:21m14081.","journal-title":"J Clin Psychiatry"},{"key":"8932_CR19","unstructured":"U.o.U. Instruction for the Registration of Congenital Anomalies. EUROCAT Central Registry, EUROCAT Guide 1.4 and Reference Documents (Last update version 07\/10\/2021), 2021."},{"key":"8932_CR20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","volume":"350","author":"RJ Edison","year":"2004","unstructured":"Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350:1579\u201382.","journal-title":"N Engl J Med"},{"key":"8932_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/1471-0528.12066","volume":"120","author":"U Winterfeld","year":"2013","unstructured":"Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Merlob P, Cuppers-Maarschalkerweerd B, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120:463\u201371.","journal-title":"BJOG"},{"key":"8932_CR22","doi-asserted-by":"publisher","first-page":"h1035","DOI":"10.1136\/bmj.h1035","volume":"350","author":"BT Bateman","year":"2015","unstructured":"Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035.","journal-title":"BMJ"},{"key":"8932_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00431-025-06119-3","volume":"184","author":"HY Kay","year":"2025","unstructured":"Kay HY, Jang HY, Kim IW, Oh JM. Pregnancy and neonatal outcomes after fetal exposure to statins among women with dyslipidemia: a nationwide cohort. Eur J Pediatr. 2025;184:340.","journal-title":"Eur J Pediatr"},{"key":"8932_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1600-0412.2012.01391.x","volume":"91","author":"LM Mudd","year":"2012","unstructured":"Mudd LM, Holzman CB, Catov JM, Senagore PK, Evans RW. Maternal lipids at mid-pregnancy and the risk of preterm delivery. Acta Obstet Gynecol Scand. 2012;91:726\u201335.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"8932_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.110.990929","volume":"124","author":"I Toleikyte","year":"2011","unstructured":"Toleikyte I, Retterst\u00f8l K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606\u201314. h.","journal-title":"Circulation"},{"key":"8932_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1471-0528.16013","volume":"127","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Williams DJ, Cheed V, Middleton LJ, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127:478\u201388.","journal-title":"BJOG"},{"key":"8932_CR27","doi-asserted-by":"publisher","first-page":"e6661","DOI":"10.1016\/j.ajog.2021.05.018","volume":"225","author":"MM Costantine","year":"2021","unstructured":"Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021;225:e6661\u201315.","journal-title":"Am J Obstet Gynecol"},{"key":"8932_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/jog.14295","volume":"46","author":"K Kumasawa","year":"2020","unstructured":"Kumasawa K, Iriyama T, Nagamatsu T, Osuga Y, Fujii T. Pravastatin for preeclampsia: from animal to human. J Obstet Gynaecol Res. 2020;46:1255\u201362.","journal-title":"J Obstet Gynaecol Res"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-08932-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:07:18Z","timestamp":1781640438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-08932-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8932"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-08932-6","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the National Center for Child Health and Development approved the study (#1502) according to the Ethical Guidelines for Medical Research Involving Human Subjects (Ministry of Health, Labor, and Welfare of Japan) and the World Medical Association Declaration of Helsinki. Informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}